1. Scrip
  2. >>Business

Can Denmark's ALK-Abello Crack The US Allergy Market?

 
• By John Davis

Increasing patient and doctor awareness of sublingual anti-allergy tablets in the US, while at the same time cutting and rationalizing its product portfolio, are components of a new three-year business strategy aimed at making Denmark's ALK-Abello a less-niche player in the global allergy market.

Dust mite
A house dust mite, a major cause of allergic rhinitis • Source: Shutterstock

Denmark's allergy therapies company, ALK-Abello AS, has become the latest European-headquartered firm to outline a corporate strategy that includes plans to crack the US allergists market, aiming to reduce the continued US reliance on "allergen extract" shots, and to boost the market for more recently developed allergy immunotherapy (AIT) treatments.

The focus on the US, with a planned DKK1bn ($159m) investment over three years, is a major cog in ALK-Abello's ambitions to transform from a niche company into a much...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business